Abstract | PURPOSE: To describe the pharmacokinetics of orally administered ABT-751 and its conjugated metabolites in children with neuroblastoma and other solid tumors and to relate pharmacokinetic parameters to toxicity and therapeutic outcomes. METHODS: Patients (median age, 11 years) with neuroblastoma (n = 37) or other solid tumors (n = 25) had pharmacokinetic sampling after the first dose of ABT-751 (75-250 mg/m(2)/day) on a 7-day or 21-day schedule. ABT-751 and its glucuronide and sulfate metabolites were quantified with an HPLC/MS/MS assay. Pharmacokinetic parameters were derived with non-compartmental methods. The relative bioavailability of more water soluble capsule and suspension formulations was assessed. RESULTS:
ABT-751 peaked in plasma at 2 h and declined monoexponentially with a t (1/2) of 5.1 h. The apparent clearance was 33 ml/min/m(2) and was age-independent. The AUC(0-infinity) increased in proportion to the dose, and at 200 mg/m(2) the median AUC(0-infinity) was 91 mcg h/ml and the C (ave) was 3.9 mcg/ml. Inter-and intra-patient variability was low. The metabolites were detected in plasma 30 min post-dose and peaked 3-5 h after the dose. The glucuronide: sulfate molar AUC(0-infinity) ratio was 0.57. Less than 1% of the dose was excreted in urine as parent drug; 13% of the dose was excreted as sulfate metabolite and 10% as glucuronide metabolite. The relative bioavailability of the water soluble capsule and suspension formulations was 105 and 93%, respectively. AUC(0-infinity) was higher in patients experiencing dose-limiting toxicity. CONCLUSIONS: Oral ABT-751 pharmacokinetics was dose-proportional and age-independent with minimal intra- and inter-patient variability in children.
|
Authors | Elizabeth Fox, John M Maris, Susan L Cohn, Wendy Goodspeed, Anne Goodwin, Marie Kromplewski, Diane Medina, Hao Xiong, Andrew Krivoshik, Brigitte Widemann, Peter C Adamson, Frank M Balis |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 66
Issue 4
Pg. 737-43
(Sep 2010)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 20044751
(Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- ABT751
- Glucuronides
- Sulfates
- Sulfonamides
|
Topics |
- Adolescent
- Area Under Curve
- Biotransformation
- Child
- Child, Preschool
- Chromatography, High Pressure Liquid
- Dose-Response Relationship, Drug
- Female
- Glucuronides
(metabolism)
- Humans
- Male
- Mass Spectrometry
- Neoplasm Recurrence, Local
- Neuroblastoma
(drug therapy, metabolism)
- Sulfates
(metabolism)
- Sulfonamides
(pharmacokinetics, therapeutic use)
- Treatment Outcome
|